European Respiratory Society (ERS) Congress 2024
Vienna, Austria 07 September 2024 - 11 September 2024
Chronic bronchitis symptoms hint at benefits of mepolizumab in COPD with T2 inflammation
The presence of chronic bronchitis symptoms in COPD with T2 inflammation drives a more pronounced and significant benefit from mepolizumab in terms of reducing CAT scores, as shown in a post hoc analysis pooling data from two phase III trials — METREX and METREO
Chronic bronchitis symptoms hint at benefits of mepolizumab in COPD with T2 inflammation
25 Sep 2024
Women with asthma more likely to need fertility treatment
Women with asthma have a higher likelihood of necessitating fertility treatment, according to a Danish nationwide historical cohort study presented at ERS 2024.
Women with asthma more likely to need fertility treatment
24 Sep 2024
Depemokimab a safe remedy for severe asthma exacerbations
Treatment with depemokimab results in a substantial decrease in exacerbations, with an acceptable safety profile, among severe asthma patients with an eosinophilic phenotype, results of the SWIFT-1 and 2 studies have shown.
Depemokimab a safe remedy for severe asthma exacerbations
20 Sep 2024
Benralizumab trumps steroids in treatment of asthma, COPD eosinophilic exacerbations
The time of steroids as the treatment of choice for asthma and chronic obstructive pulmonary disease (COPD) exacerbations appears to be nearing its end with the arrival of a new monoclonal antibody therapy, according to the results of the ABRA study.
